|1.||Sava, Gianni: 21 articles (12/2015 - 07/2002)|
|2.||Sava, G: 17 articles (10/2015 - 04/2000)|
|3.||Bergamo, A: 11 articles (10/2015 - 04/2000)|
|4.||Bergamo, Alberta: 10 articles (12/2015 - 11/2002)|
|5.||Cocchietto, M: 10 articles (01/2015 - 11/2000)|
|6.||Zorzet, S: 8 articles (04/2006 - 04/2000)|
|7.||Beijnen, Jos H: 6 articles (02/2015 - 11/2002)|
|8.||Cocchietto, Moreno: 6 articles (08/2004 - 11/2002)|
|9.||Alessio, Enzo: 5 articles (02/2015 - 12/2002)|
|10.||Alessio, E: 5 articles (04/2005 - 04/2000)|
04/01/2000 - "Similarly to what is normally observed with NAMI-A, the treatment with the dimeric complexes was scarcely effective against the growth of the primary tumor. "
01/01/2007 - "The assay is now successfully used to support pharmacokinetic studies in cancer patients treated with NAMI-A."
08/01/2004 - "treatment allows study of the effects of NAMI-A on in vivo tumor cells exposed to millimolar concentrations for a relatively prolonged time. "
06/01/2004 - "This Phase I study was designed to determine the maximum-tolerated dose (MTD), profile of adverse events, and dose-limiting toxicity of NAMI-A in patients with solid tumors. "
09/14/2014 - "Limited activity of NAMI-A against primary tumor suggests that its use in combination with other anticancer drug(s) might present a more desirable therapeutic outcome. "
|2.||Neoplasm Metastasis (Metastasis)
10/01/2015 - "The aim of the study was to examine the interaction of NAMI-A with TGF-β1 in the process of metastasis formation. "
03/01/1999 - "The success of NAMI-A against metastasis should stimulate laboratory studies with appropriate experimental models to predict clinical activity, since the use of experimental conditions closely similar to those of human tumours should help the identification of more active compounds."
12/21/2015 - "The capacity of NAMI-A to modulate the relationship established between metastatic cells and their microenvironment suggests that metal-based drugs shall be viewed as an opportunity for the treatment of tumour metastases. "
01/28/2015 - "This observation supports the thesis that the reduction of the drug before injection must be considered relevant for the pharmacological activity of NAMI-A against tumour metastases. "
10/01/2012 - "Considering the dependence of NAMI-A cell cycle arrest on the dose and on the length of cell challenge, and considering the prolonged NAMI-A t1/2 in vivo in the lungs, we proved an even greater perturbation of the cell cycle regulating pathways in lung metastases of NAMI-A treated mice. "
09/01/2000 - "The study focuses on the effects of NAMI-A on leukocyte infiltration into the primary tumour of MCa mammary carcinoma, implanted subcutaneously (s.c.) or intramuscularly (i.m.) into CBA mice. "
02/01/2015 - "In MCa mammary carcinoma of CBA mice, NAMI-A (35 mg/kg/day i.p. "
10/01/2004 - "NAMI-A, given to mice bearing MCa mammary carcinoma at advanced stages of growth, increased the thickness of connective tissue and induced recruitment of leukocytes, particularly in the peritumour capsule. "
01/01/2001 - " aim of this study was to investigate the potential use of NAMI-A by the oral route to treat lung metastases of MCa mammary carcinoma in the CBA mouse. "
10/07/2015 - "The genes differentially expressed by NAMI-A are evaluated through whole-transcriptome analysis and RNA-sequencing in the metastatic MDA-MB-231 mammary carcinoma cells, in comparison to the non-tumorigenic HBL-100 mammary gland cells. "
|4.||Lewis Lung Carcinoma
02/01/2003 - "In this study, we evaluated the effects of different routes of administration of NAMI-A on the distribution to primary tumor, lungs and kidneys in BD2F1 hybrids with Lewis lung carcinoma or in CBA inbred mice with MCa mammary carcinoma. "
03/01/1999 - "NAMI-A significantly reduced the growth of lung metastases either when given prior to surgery (early growing tumours) on TS/A adenocarcinoma or after surgical ablation of primary tumours (already established lung metasases) on Lewis lung carcinoma. "
05/01/2003 - "The transplantation of Lewis lung carcinoma cells, harvested from the primary tumor of mice treated with 35 mg/kg/day NAMI-A for six consecutive days, a dose active on metastases, shows no change in primary tumor take and growth but a significant reduction in formation of spontaneous lung metastases. "
09/01/2000 - "NAMI-A, given with a cycle of daily treatments for six consecutive days on advanced tumours at 35 mg/kg/day, markedly reduces lung metastasis independently of the tumour type (Lewis lung carcinoma, MCa mammary carcinoma or TS/A adenocarcinoma) being treated and of the site of tumour implantation (s.c. "
04/01/1999 - "Conversely, cisplatin (2 mg/kg/day for 6 days) was as effective as NAMI-A on MCa mammary carcinoma and TS/A adenocarcinoma and less effective than NAMI-A on Lewis lung carcinoma. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/2015 - "This phase I/II study determined the maximal tolerable dose, dose limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of ruthenium compound NAMI-A in combination with gemcitabine in Non-Small Cell Lung Cancer patients after first line treatment. "
02/01/2015 - "Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy."
|3.||dichlorotetrakis(dimethyl sulfoxide)ruthenium II (trans-Ru)
|7.||DNA (Deoxyribonucleic Acid)
|8.||indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))
|1.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)